VAERS reports by lot

Janssen (J&J) COVID-19 lot 202F21A: VAERS reports

55 VAERS reports list lot 202F21A as a Janssen (J&J) COVID-19 vaccine, received between 2022-06-23 and 2023-06-15. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
55
Reports
7%
Marked serious
1
With a death outcome
12
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological4535%
General / Systemic (non-local)2620%
Cardiac / Cardiovascular1310%
Dermatological (non-injection-site)118%
Respiratory86%
Gastrointestinal86%
Thrombotic / Hematological43%
Allergic / Anaphylactic43%
Musculoskeletal32%
Reproductive / Menstrual32%
Injection-site / Local reaction32%
Psychiatric / Neuropsychiatric22%

Where reports came from

U.S. state of the reporter, where given (top 12).

Kentucky7
New York5
California4
Florida4
Massachusetts4
Indiana4
Washington3
North Carolina2
Virginia2
Texas2
Idaho2
Connecticut2

Reports by month received

2022-061
2022-078
2022-0813
2022-094
2022-106
2022-113
2022-126
2023-013
2023-027
2023-031
2023-052
2023-061

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.